secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001193125-24-023462
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 5.03, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre appoints Mark McKenna as director; CEO severance amended
--------------------------------------------------------------

- Alison Lawton resigned from Board effective Feb 1, 2024; no disagreement cited.
- Mark McKenna appointed Class I director; former CEO of Prometheus Biosciences (acquired by Merck).
- CEO Cameron Turtle's severance increased by 0.5x target bonus in change-in-control event.
- McKenna granted option for 40,000 shares under equity plan; consulting agreement grants 477,000 options.
- Board adopted amended bylaws, new code of conduct, and indemnification agreements for directors/officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/d732838d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-023462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer